HBP vs. TH, SCYB, COM, NVH, MDNA, IGX, COV, ONC, PDP, and MBX
Should you be buying Helix BioPharma stock or one of its competitors? The main competitors of Helix BioPharma include Theratechnologies (TH), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), Medicenna Therapeutics (MDNA), IntelGenx Technologies (IGX), Covalon Technologies (COV), Oncolytics Biotech (ONC), Pediapharm (PDP), and Microbix Biosystems (MBX). These companies are all part of the "biotechnology" industry.
Helix BioPharma vs.
Theratechnologies (TSE:TH) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, community ranking, profitability, media sentiment, valuation and analyst recommendations.
Theratechnologies has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500. Comparatively, Helix BioPharma has a beta of -0.84, suggesting that its stock price is 184% less volatile than the S&P 500.
Theratechnologies has higher revenue and earnings than Helix BioPharma. Theratechnologies is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks.
51.2% of Theratechnologies shares are held by institutional investors. 1.2% of Theratechnologies shares are held by company insiders. Comparatively, 2.2% of Helix BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Helix BioPharma has a net margin of 0.00% compared to Theratechnologies' net margin of -3.75%. Helix BioPharma's return on equity of 1,803.57% beat Theratechnologies' return on equity.
In the previous week, Helix BioPharma had 1 more articles in the media than Theratechnologies. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for Theratechnologies. Helix BioPharma's average media sentiment score of 0.67 beat Theratechnologies' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the news media.
Theratechnologies received 204 more outperform votes than Helix BioPharma when rated by MarketBeat users. Likewise, 63.53% of users gave Theratechnologies an outperform vote while only 63.46% of users gave Helix BioPharma an outperform vote.
Summary
Theratechnologies beats Helix BioPharma on 10 of the 16 factors compared between the two stocks.
Get Helix BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HBP and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Helix BioPharma Competitors List
Related Companies and Tools
This page (TSE:HBP) was last updated on 2/22/2025 by MarketBeat.com Staff
